Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Jacobs & Co. CA

Jacobs & Co. CA reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.5% in the 3rd quarter, Holdings Channel reports. The fund owned 43,812 shares of the medical instruments supplier’s stock after selling 4,095 shares during the period. Jacobs & Co. CA’s holdings in Becton, Dickinson and Company were worth $10,563,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Jennison Associates LLC lifted its stake in shares of Becton, Dickinson and Company by 4.9% in the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC boosted its stake in shares of Becton, Dickinson and Company by 2,086.7% during the 1st quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after acquiring an additional 49,559 shares in the last quarter. Franklin Street Advisors Inc. NC acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter valued at about $11,998,000. Avity Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 3.5% in the 1st quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after purchasing an additional 5,527 shares in the last quarter. Finally, Caden Capital Partners LP increased its stake in shares of Becton, Dickinson and Company by 26.7% in the 4th quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after purchasing an additional 17,599 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a report on Tuesday. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Evercore ISI increased their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $239.76 on Thursday. The company has a fifty day simple moving average of $236.55 and a 200-day simple moving average of $235.57. The firm has a market capitalization of $69.29 billion, a price-to-earnings ratio of 52.81, a PEG ratio of 1.92 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. Becton, Dickinson and Company’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.96 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.